T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback